Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial., Journal of Clinical Oncology, vol.15, issue.6, pp.2403-2416, 1997. ,
DOI : 10.1200/JCO.1997.15.6.2403
Adjuvant therapy in pancreatic cancer World journal of gastroenterology: WJG, pp.14733-14779, 2014. ,
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines, British journal of cancer, vol.8320, issue.8, pp.1069-76, 2000. ,
Treatment of metastatic pancreatic adenocarcinoma: a review, Oncology, vol.28, issue.1, pp.70-402, 2014. ,
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial, JNCI Journal of the National Cancer Institute, vol.107, issue.2, 2015. ,
DOI : 10.1093/jnci/dju413
Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase, Biochemical Pharmacology, vol.45, issue.9, pp.1857-61, 1993. ,
DOI : 10.1016/0006-2952(93)90444-2
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs , in press, Expert Opin Drug Metab Toxicol, 2014. ,
Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies, Journal of Clinical Oncology, vol.28, issue.1, pp.160-165, 2009. ,
DOI : 10.1200/JCO.2009.24.4491
Molecular epidemiology in cancer research Molecular aspects of medicine, pp.359-432, 1998. ,
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug metabolism and disposition: the biological fate of chemicals, pp.541-546, 2012. ,
Human cytidine deaminase: A biochemical characterization of its naturally occurring variants, International Journal of Biological Macromolecules, vol.63, pp.64-74, 2014. ,
DOI : 10.1016/j.ijbiomac.2013.10.029
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research, pp.1797-803, 2008. ,
Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples, Nucleosides, Nucleotides and Nucleic Acids, vol.26, issue.6-7, pp.720-725, 2008. ,
DOI : 10.1126/science.286.5439.487
The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: A meta-analysis. The International journal of biological markers, pp.224-256, 2014. ,
Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism, Journal of Clinical Oncology, vol.25, issue.1, pp.32-42, 2006. ,
DOI : 10.1200/JCO.2006.06.7405
Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism, The Oncologist, vol.16, issue.6, pp.820-854, 2011. ,
DOI : 10.1634/theoncologist.2010-0259
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen, Pharmacogenomics, vol.14, issue.9, pp.1047-51, 2013. ,
DOI : 10.2217/pgs.13.93
Liquid chromatography???tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma, Journal of Chromatography B, vol.906, pp.1-8, 2012. ,
DOI : 10.1016/j.jchromb.2012.07.033
Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate, British Journal of Clinical Pharmacology, vol.14, issue.3, pp.326-359, 2008. ,
DOI : 10.1111/j.1365-2125.2003.02051.x
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism, European Journal of Clinical Pharmacology, vol.14, issue.4 Suppl 11 ,
DOI : 10.1007/s00228-010-0799-0
URL : https://hal.archives-ouvertes.fr/hal-00612989
Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients, Journal of Thoracic Oncology, vol.6, issue.12, pp.2018-2605, 2011. ,
DOI : 10.1097/JTO.0b013e3182307e1f
Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter, Human Genetics, vol.206, issue.Suppl 1, pp.276-83, 2006. ,
DOI : 10.1007/s00439-006-0142-0
Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients, Clinical Pharmacokinetics, vol.9, issue.3, pp.549-58, 2010. ,
DOI : 10.2165/11532970-000000000-00000